Patient Sampling and Genomics Core
患者采样和基因组学核心
基本信息
- 批准号:10170862
- 负责人:
- 金额:$ 37.09万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-09-20 至 2026-06-30
- 项目状态:未结题
- 来源:
- 关键词:AcuteAcute Lung InjuryAdult Respiratory Distress SyndromeAfrican AmericanBioinformaticsBiometryBloodBlood specimenBronchoalveolar LavageClinicalClinical DataCodeCritical IllnessDataDevelopmentDiagnosticDisease OutcomeDoctor of PhilosophyEnrollmentEtiologyExcisionGenomicsHispanicsHumanHuman ResourcesImmune ToleranceIndividualInflammatoryInformaticsInstitutional Review BoardsLatinoLungLymphocyteMechanical ventilationMediatingMedicineMethodologyPathway interactionsPatientsPeripheral Blood Mononuclear CellPharmacologyPhasePhenotypePneumoniaPopulationProcessProtocols documentationPulmonologyReportingResearchResearch PersonnelResolutionResourcesRoleSafetySamplingSepsisSeveritiesSeverity of illnessSpecialistSpecimenStructureUnderrepresented PopulationsUniversitiesWorkbiobankclinical databaseclinical phenotypeimprovedinnovationlung injurymacrophagenovel strategiespatient populationpatient subsetsprofessorprogramsrepairedrepositoryrespiratorysample collectionsingle-cell RNA sequencingtranscriptome sequencingtranscriptomicstreatment response
项目摘要
PROJECT SUMMARY / ABSTRACT
A critical translational component of this Program Project involves the correlative analysis of macrophages (Mφ)
isolated from critically ill patients suffering from sepsis, pneumonia, and other acute insults that result in the
devastating clinical syndrome of Acute Respiratory Distress Syndrome (ARDS). The Patient Sampling and
Genomics Core (Core D) will perform the central function of collecting these Mφ samples and establishing and
maintaining a clinical database of disease severity. Feasibility for obtaining sufficient samples for the proposed
studies will be greatly enhanced through extensive utilization of a non-bronchoscopic BAL (NBBAL) approach,
which results in diagnostic yields similar to bronchoscopic BAL and has an excellent safety profile in critically ill
patients requiring mechanical ventilation. In addition, blood will be collected for isolation of peripheral blood
mononuclear cells (PBMCs) for comparison with lung samples. Longitudinal samples will be collected from a
subset of patients. Additionally, Core D will provide biostatistical analysis on these clinical samples as well as
bioinformatic analysis on samples from all Projects, including bulk RNA-seq analysis, and single-cell RNA-seq
(scRNA-seq) processing and analysis, as described in the individual Projects. A spectrum of clinical severity will
be obtained to correlate disease outcomes with flow cytometric, transcriptomic, and functional analyses of Mφs,
focusing on pathways relevant to each of the four Projects.
Innovative aspects of this Core include the following: a) development of an unique biorepository of lung
Mφ samples from patients with ARDS, including longitudinal samples from a subset of patients to characterize
changes in lung Mφ populations during the phases of ARDS; b) scRNA-seq analysis of patient lung Mφ,
representing a substantial methodological advance in Mφ analysis compared to other recent studies; c) extensive
utilization of the NBBAL approach to greatly enhance sample collection since it can be performed safely and
with high yield by respiratory therapists and fellow trainees; d) an integrated Core structure that combines patient
sample acquisition with biostatistical and bioinformatic expertise and resources to maximize efficient utilization
of these clinical data; e) sample collection from a diverse ICU patient population of under-represented and
insufficiently studied groups (30-40% African-American and 30-40% Hispanic/Latino patients). f) Comparison of
expression profiles in lung Mφ populations from ARDS patients with circulating PBMCs after removal of
lymphocytes, which will improve the reported poor correlation between these sample types; g) inclusion of
immune paralysis as phenotypic characterization of patient samples, which has not been evaluated in past
studies of ARDS AMφ clinical samples; h) enhanced focus on sepsis and pneumonia-induced ARDS as the
primary etiologies characterized by intensive lung Mφ analysis.
项目摘要/摘要
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
STEVEN M DUDEK其他文献
STEVEN M DUDEK的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('STEVEN M DUDEK', 18)}}的其他基金
Pathobiology of MRSA-induced Endothelial Permeability and Acute Lung Injury
MRSA 诱导的内皮通透性和急性肺损伤的病理学
- 批准号:
10608606 - 财政年份:2022
- 资助金额:
$ 37.09万 - 项目类别:
Fostering Academic Physician-Investigators Treating High Risk Populations
培养治疗高危人群的学术医师研究人员
- 批准号:
10647841 - 财政年份:2021
- 资助金额:
$ 37.09万 - 项目类别:
Fostering Academic Physician-Investigators Treating High Risk Populations
培养治疗高危人群的学术医师研究人员
- 批准号:
10459247 - 财政年份:2021
- 资助金额:
$ 37.09万 - 项目类别:
Postdoctoral Training Program in Pulmonary and Critical Care Translational Research
肺部和重症监护转化研究博士后培训项目
- 批准号:
10472480 - 财政年份:2019
- 资助金额:
$ 37.09万 - 项目类别:
Postdoctoral Training Program in Pulmonary and Critical Care Translational Research
肺部和重症监护转化研究博士后培训项目
- 批准号:
10700843 - 财政年份:2019
- 资助金额:
$ 37.09万 - 项目类别:
Postdoctoral Training Program in Pulmonary and Critical Care Translational Research
肺部和重症监护转化研究博士后培训项目
- 批准号:
9791769 - 财政年份:2019
- 资助金额:
$ 37.09万 - 项目类别:
Postdoctoral Training Program in Pulmonary and Critical Care Translational Research
肺部和重症监护转化研究博士后培训项目
- 批准号:
10198029 - 财政年份:2019
- 资助金额:
$ 37.09万 - 项目类别:
Crosstalk between S1P Receptor 1/S1P1 and P-Selectin/Selp in Regulation of Inflammatory Vascular Permeability
S1P 受体 1/S1P1 和 P-选择素/Selp 之间的串扰调节炎症血管通透性
- 批准号:
10871784 - 财政年份:2016
- 资助金额:
$ 37.09万 - 项目类别:
相似海外基金
Combinatorial cytokine-coated macrophages for targeted immunomodulation in acute lung injury
组合细胞因子包被的巨噬细胞用于急性肺损伤的靶向免疫调节
- 批准号:
10648387 - 财政年份:2023
- 资助金额:
$ 37.09万 - 项目类别:
Inducible HMGB1 antagonist for viral-induced acute lung injury.
诱导型 HMGB1 拮抗剂,用于治疗病毒引起的急性肺损伤。
- 批准号:
10591804 - 财政年份:2023
- 资助金额:
$ 37.09万 - 项目类别:
MAP2K1 AND MAP2K2 IN ACUTE LUNG INJURY AND RESOLUTION
MAP2K1 和 MAP2K2 在急性肺损伤中的作用及缓解
- 批准号:
10741574 - 财政年份:2023
- 资助金额:
$ 37.09万 - 项目类别:
Lung epithelial cell-derived C3 in acute lung injury
肺上皮细胞衍生的 C3 在急性肺损伤中的作用
- 批准号:
10720687 - 财政年份:2023
- 资助金额:
$ 37.09万 - 项目类别:
Examining the role of TRMT1 and tRNA methylation in acute lung injury and ARDS
检查 TRMT1 和 tRNA 甲基化在急性肺损伤和 ARDS 中的作用
- 批准号:
10719249 - 财政年份:2023
- 资助金额:
$ 37.09万 - 项目类别:
Development of a new treatment for COVID-19-related acute lung injury targeting the microbiota-derived peptide corisin
针对微生物群衍生肽 corisin 开发治疗 COVID-19 相关急性肺损伤的新疗法
- 批准号:
23K07651 - 财政年份:2023
- 资助金额:
$ 37.09万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Probing immunovascular mechanobiology in pneumonia-associated acute lung injury at the single capillary level
在单毛细血管水平探讨肺炎相关急性肺损伤的免疫血管力学生物学
- 批准号:
10679944 - 财政年份:2023
- 资助金额:
$ 37.09万 - 项目类别:
The amyloid precursor protein protects against acute lung injury
淀粉样前体蛋白可预防急性肺损伤
- 批准号:
10575258 - 财政年份:2023
- 资助金额:
$ 37.09万 - 项目类别:
Role of macrophages and miRNA in regulating lung macrophage polarization and lung pathogenesis during respiratory virus-induced acute lung injury in normal and diabetic Syrian hamsters.
正常和糖尿病叙利亚仓鼠呼吸道病毒引起的急性肺损伤期间巨噬细胞和 miRNA 在调节肺巨噬细胞极化和肺部发病机制中的作用。
- 批准号:
10701207 - 财政年份:2023
- 资助金额:
$ 37.09万 - 项目类别:
Roles of N-glycans on neutrophil beta2 integrins in progression of acute lung injury
N-聚糖对中性粒细胞β2整合素在急性肺损伤进展中的作用
- 批准号:
10837431 - 财政年份:2023
- 资助金额:
$ 37.09万 - 项目类别:














{{item.name}}会员




